Genfit S.A. (NASDAQ:GNFT) Sees Large Drop in Short Interest

Genfit S.A. (NASDAQ:GNFT - Get Free Report) saw a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 51,300 shares, a drop of 23.0% from the April 30th total of 66,600 shares. Based on an average daily volume of 13,200 shares, the days-to-cover ratio is presently 3.9 days. Currently, 0.1% of the company's stock are sold short.

Genfit Stock Down 0.9%

NASDAQ:GNFT traded down $0.04 during mid-day trading on Wednesday, hitting $4.47. The company had a trading volume of 997 shares, compared to its average volume of 13,004. The business has a fifty day simple moving average of $3.86 and a 200-day simple moving average of $3.81. The company has a current ratio of 3.74, a quick ratio of 3.74 and a debt-to-equity ratio of 0.61. Genfit has a 1 year low of $2.55 and a 1 year high of $6.42.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a "buy" rating and issued a $13.00 price objective on shares of Genfit in a research report on Friday, February 7th.

Hedge Funds Weigh In On Genfit

An institutional investor recently bought a new position in Genfit stock. OLD Mission Capital LLC bought a new stake in Genfit S.A. (NASDAQ:GNFT - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 22,238 shares of the company's stock, valued at approximately $76,000. 2.24% of the stock is owned by institutional investors.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.